Literature DB >> 1848861

Decreased luminol-dependent chemiluminescence response of neutrophils to recombinant human tumour necrosis factor in patients with gastric cancer.

I A Schepetkin1, N V Cherdyntseva, E V Borunov, I L Skutina, S A Naumov.   

Abstract

Production of reactive oxygen species by neutrophils was analyzed by a chemiluminometric method in the presence of luminol in ten healthy donors, eight patients with gastric cancer and ten patients with gastric precancer. The neutrophil chemiluminominescence response to recombinant tumour necrosis factor (rTNF) was almost five times lower in the gastric patients when compared with healthy donors and precancer patients. The chemiluminescence response to zymosan was decreased only in the gastric cancer patients with chemiluminescence index activation (CTNF) less than 1. The observed changes of neutrophil functions are thought to result in a decrease of neutrophil cytotoxic activity in gastric cancer patients.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1848861     DOI： 10.1007/bf01613143

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  19 in total

1.  Regulation of neutrophil migration and superoxide production by recombinant tumor necrosis factors-alpha and -beta: comparison to recombinant interferon-gamma and interleukin-1 alpha.

Authors:  I S Figari; N A Mori; M A Palladino
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

2.  Effects of tumour necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, respiratory burst and degranulation.

Authors:  A Ferrante; M Nandoskar; A Walz; D H Goh; I C Kowanko
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

Review 3.  Tumour necrosis factor.

Authors:  F R Balkwill
Journal:  Br Med Bull       Date:  1989-04       Impact factor: 4.291

4.  Measurement of chemiluminescence in freshly drawn human blood. II. Clinical application of zymosan-induced chemiluminescence.

Authors:  M Heberer; M Ernst; M Dürig; M Allgöwer; H Fischer
Journal:  Klin Wochenschr       Date:  1982-12-01

5.  Comparison between luminol- and lucigenindependent chemiluminescence of polymorphonuclear leukocytes.

Authors:  H Aniansson; O Stendahl; C Dahlgren
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-12

6.  Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma.

Authors:  M Sekimoto; I Kokunai; T Shimano; T Kobayashi; T Takeda; N Haruna; A Yamamoto; T Mori
Journal:  J Clin Lab Immunol       Date:  1988-11

7.  Nitroblue tetrazolium test in patients with neoplasma during surgical treatment.

Authors:  A Korenkiewicz; K Merkiel; J Prokopowicz
Journal:  Neoplasma       Date:  1983       Impact factor: 2.575

8.  Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils.

Authors:  Y H Atkinson; W A Marasco; A F Lopez; M A Vadas
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

9.  Tumour necrosis factor beta (lymphotoxin) inhibits locomotion and stimulates the respiratory burst and degranulation of neutrophils.

Authors:  A Ferrante; M Nandoskar; E J Bates; D H Goh; L J Beard
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

10.  Hereditary myeloperoxidase deficiency.

Authors:  M Kitahara; H J Eyre; Y Simonian; C L Atkin; S J Hasstedt
Journal:  Blood       Date:  1981-05       Impact factor: 22.113
View more
  1 in total

1.  Different metabolic effects of ganglioside GM1 in brain synaptosomes and phagocytic cells.

Authors:  N F Avrova; I O Zakharova; V A Tyurin; Y Y Tyurina; I A Gamaley; I A Schepetkin
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.